aldosterone has been researched along with Central Serous Retinopathy in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone treatment was associated with the improvement of chronic CSC." | 6.84 | The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017) |
| "The purpose of this study were to compare the levels of serum cortisol, aldosterone, testosterone, dehydroepiandrosterone (DHEA), and renin hormone between patients with central serous chorioretinopathy (CSC) and a control group, and to investigate whether there was a difference regarding serum hormone levels in patients with acute/chronic CSC." | 3.88 | The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. ( Çiloğlu, E; Dogan, NC; Unal, F, 2018) |
| "Spironolactone treatment was associated with the improvement of chronic CSC." | 2.84 | The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study. ( Gong, Q; Liu, QH; Sun, XH; Yuan, ST, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, S | 1 |
| Cui, K | 1 |
| Wu, P | 1 |
| Wu, B | 1 |
| Lu, X | 1 |
| Huang, R | 1 |
| Tang, X | 1 |
| Lin, J | 1 |
| Yang, B | 1 |
| Zhao, J | 1 |
| He, Q | 1 |
| Liang, X | 1 |
| Xu, Y | 1 |
| Higashide, T | 3 |
| Hirooka, K | 3 |
| Kometani, M | 3 |
| Sugiyama, K | 3 |
| Çiloğlu, E | 1 |
| Unal, F | 1 |
| Dogan, NC | 1 |
| Brinks, J | 1 |
| van Dijk, EHC | 1 |
| Habeeb, M | 1 |
| Nikolaou, A | 1 |
| Tsonaka, R | 1 |
| Peters, HAB | 1 |
| Sips, HCM | 1 |
| van de Merbel, AF | 1 |
| de Jong, EK | 1 |
| Notenboom, RGE | 1 |
| Kielbasa, SM | 1 |
| van der Maarel, SM | 1 |
| Quax, PHA | 1 |
| Meijer, OC | 1 |
| Boon, CJF | 1 |
| Gong, Q | 1 |
| Sun, XH | 1 |
| Yuan, ST | 1 |
| Liu, QH | 1 |
| Zhao, M | 1 |
| Célérier, I | 1 |
| Bousquet, E | 1 |
| Jeanny, JC | 1 |
| Jonet, L | 1 |
| Savoldelli, M | 1 |
| Offret, O | 1 |
| Curan, A | 1 |
| Farman, N | 1 |
| Jaisser, F | 1 |
| Behar-Cohen, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02153125] | Phase 2 | 30 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Eplerenone for Central Serous Chorioretinopathy: A Pilot Study[NCT01822561] | Phase 2 | 17 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Visual acuity will be measured with standard eye charts, with manifest refraction at the initiation and conclusion of treatment. Although an important measure, this was not chosen as the primary outcome measure, as some patients with central serous chorioretinopathy may have a normal visual acuity when properly refracted (refraction can change with elevation of the macula by sub-retinal fluid) (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | logMAR (Mean) |
|---|---|
| Patients That Took Eplerenone | -0.03 |
Automated software to calculate the thickness of the macula is standard on commercial OCT devices. Macular thickness before and after treatment will be assessed and compared. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | Microns (Mean) |
|---|---|
| Patients That Received Eplerenone | -26 |
Eplerenone can cause elevation of serum potassium. After initial screening, serum potassium was evaluated at 1 and 4 weeks after baseline. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | mEq/L (Mean) |
|---|---|
| Patients That Received Eplerenone | 0.11 |
Choroidal thickness can be measured using optical coherence tomography, and is known to be affected in patients with central serous chorioretinopathy. Thickness of the choroid under the fovea will be manually calculated in both the study eye. (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | microns (Mean) |
|---|---|
| Patients That Received Eplerenone | 29.8 |
Optical coherence tomography is an imaging technique capable of extremely high resolution (~5-7 microns) imaging of the macula, and is able to detect the presence and amount of subretinal fluid present, the key anatomic abnormality in Central Serous Chorioretinopathy (NCT01822561)
Timeframe: Baseline and 1 month after treatment
| Intervention | participants (Number) |
|---|---|
| Patients That Took Eplerenone | 0 |
1 trial available for aldosterone and Central Serous Retinopathy
| Article | Year |
|---|---|
The relation of the serum aldosterone level and central serous chorioretinopathy - a pilot study.
Topics: Adult; Aldosterone; Central Serous Chorioretinopathy; Choroid; Female; Fluorescein Angiography; Huma | 2017 |
5 other studies available for aldosterone and Central Serous Retinopathy
| Article | Year |
|---|---|
Melatonin prevents experimental central serous chorioretinopathy in rats.
Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Ligands; Melatonin; Rats | 2022 |
Aldosterone as a Possible Contributor to Eye Diseases.
Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem | 2022 |
Aldosterone as a Possible Contributor to Eye Diseases.
Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem | 2022 |
Aldosterone as a Possible Contributor to Eye Diseases.
Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem | 2022 |
Aldosterone as a Possible Contributor to Eye Diseases.
Topics: Aldosterone; Animals; Central Serous Chorioretinopathy; Diabetic Retinopathy; Glaucoma; Macular Edem | 2022 |
The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.
Topics: Adult; Aldosterone; Biomarkers; Central Serous Chorioretinopathy; Choroid; Dehydroepiandrosterone; F | 2018 |
The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy.
Topics: Aged; Aged, 80 and over; Aldosterone; Cadherins; Cells, Cultured; Central Serous Chorioretinopathy; | 2018 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy.
Topics: Adult; Aldosterone; Animals; Central Serous Chorioretinopathy; Choroid; Corticosterone; Eplerenone; | 2012 |